Why JD.com Stock Topped the Market Today
The company posted its first-quarter earnings.
It notched double-digit increases in revenue and profitability, and topped analyst estimates for both.
10 stocks we like better than JD.com ›
Investors were certainly buying what sprawling Chinese e-commerce company JD.com (NASDAQ: JD) was advertising on Tuesday. On offer was the company's latest set of quarterly results, which beat estimates and helped push its U.S.-listed American depositary shares (ADSs) more than 3% higher in price. That compared quite favorably to the 0.7% upward crawl of the bellwether S&P 500 index.
For its opening quarter of 2025, JD.com booked revenue of slightly over 301 billion yuan ($47 billion), which represented a nearly 16% improvement on a year-over-year basis.
The online retailer managed to post a far higher leap in profitability, with non-GAAP (adjusted) net income zooming 43% higher to 12.8 billion yuan ($1.8 billion). On a per-share basis, this figure was 8.41 yuan ($1.16) per ADS.
Both key fundamentals easily topped the consensus analyst estimates. On average, the pundits tracking JD.com stock were anticipating the company would earn slightly under 291 million yuan ($40 million) in revenue, filtering down into an adjusted net-income figure of 7.09 yuan ($.98) per ADS.
In the earnings release, JD.com attributed its growth to both external and internal factors. It quoted CEO Sandy Xu as saying that "Our performance was supported by improving consumer sentiment and continued enhancements to JD's supply chain capabilities and user experience."
Xu also said the company benefited from growth in its overall user count too.
Although Chinese economic growth isn't what it once was, JD.com's performance indicates the consumer sector might be staging something of a comeback. If that continues, not only this company but numerous other retailers could very well be in a position to benefit. This might be quite the sector for investors to watch.
Before you buy stock in JD.com, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and JD.com wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $598,613!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $753,878!*
Now, it's worth noting Stock Advisor's total average return is 922% — a market-crushing outperformance compared to 169% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of May 12, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends JD.com. The Motley Fool has a disclosure policy.
Why JD.com Stock Topped the Market Today was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
FREMONT, Calif., June 03, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate the potential of NeXT Personal to enable earlier detection in a cancer with high recurrence rates. The results were presented yesterday by Jyoti Mayadev, MD, from the University of California San Diego, at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago in an oral presentation titled "Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses." The results from this study were also simultaneously published in the journal Annals of Oncology. Samples were analyzed from patients with cervical cancer who had enrolled in the original CALLA clinical trial. In this new study analysis, NeXT Personal was used to look for small traces of ctDNA in blood samples from a cohort of 186 patients with locally advanced cervical cancer. Dr. Mayadev's team found that overall ctDNA levels after chemoradiotherapy (CRT) treatment were strongly predictive of risk of cervical cancer progression. "Despite standard chemoradiotherapy, up to half of patients with locally advanced cervical cancer relapse, underscoring the urgent need for better prognostic tools. In the CALLA phase 3 study, ultrasensitive, tumor-informed ctDNA analysis emerged as a powerful predictor of progression and survival—detecting relapse up to ~16 months before imaging. These findings highlight ctDNA's potential to guide treatment decisions and personalize care in high-risk cervical cancer," said Dr. Mayadev. Key findings presented: Detection of ctDNA following CRT was independently prognostic of patient outcomes. Risk of progression and death were at least 95% lower for patients where ctDNA was not detected ~3 months after completing CRT. Detection of ctDNA after CRT was associated with high subsequent risk of disease progression, and was detected a median of ~5 months and up to ~16 months earlier than by imaging scans. High ctDNA levels (≥ median) at baseline was associated with higher risk of progression and death. "We are excited to see the results presented for NeXT Personal in this large phase 3 study in cervical cancer," said Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D at Personalis. "Cervical cancer is the fourth most common cancer for women globally, resulting in hundreds of thousands of deaths each year. The new results show the strong potential for an ultrasensitive MRD test like NeXT Personal to inform treatment for cervical cancer patients." About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor or predict a patient's response to therapy or risk of cancer recurrence, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. Not affiliated with or endorsed by ASCO. View source version on Contacts Investors: Caroline Cornerinvestors@ 415-202-5678 Media Contact pr@
Yahoo
28 minutes ago
- Yahoo
Why These Market Forecasters Expect Stocks To End the Year at Record Highs
Deutsche Bank analysts led by Chief US Equity & Global Strategist Binky Chadha on Tuesday raised their year-end S&P 500 target to 6,550. That suggests about 10% upside from Tuesday's close. And it would be nearly 7% above the index's record close from earlier this year. Investor positioning, they said, is close to neutral and assumes tariffs will be a slight drag on earnings growth this Wall Street forecasters see stocks closing out 2025 at record highs—despite a shaky start to the year. Deutsche Bank analysts led by Chief US Equity & Global Strategist Binky Chadha on Tuesday raised their year-end S&P 500 target to 6,550, a number suggesting about 10% upside from Tuesday's close. That would be nearly 7% above the index's record close from earlier this year. Investor positioning, they said, is close to neutral and assumes tariffs will be a slight drag on earnings growth this year. 'However, if there is confidence that tariff impacts will be modest and temporary, we expect discretionary investors to look through any slowing in growth and turn overweight in anticipation of a rebound,' they wrote. The analysts expect robust corporate demand to shrink the supply of stock on public markets. They forecast companies will spend $1.1 trillion on stock buybacks this year, thanks to resilient earnings. Deutsche Bank raised its estimate of the S&P 500's aggregate full-year earnings per share to $267 from $240. The firm entered the year forecasting index-level earnings of $282 per share. But it slashed that outlook in mid-April shortly after President Trump paused 'Liberation Day' tariffs for 90 days and lifted rates on Chinese goods to 145% at a minimum. Earnings, they estimated, would suffer from a prohibitively high effective tariff rate and the lingering possibility of a prolonged trade war. The outlook improved last month when the U.S. and China agreed to slash their respective tariff rates while officials negotiated a more comprehensive trade deal. Tensions between the world's two largest economies linger: This weekend each party accusing the other of violating their tentative agreement. Still, the White House's approach to tariff negotiations has some market watchers feeling optimistic. Deutsche Bank's analysts take the White House's decision to pause 'Liberation Day' tariffs just hours after they took effect, 'before the emergence of any legal barriers or economic or political pain,' as a sign that 'if negative impacts of tariffs do materialize, we will get further relents.' As such, Deutsche Bank expects this year's rally to 6,550 to benefit investors who bet on Trump relenting. 'Despite the rhetoric to the contrary, the 2018-2019 dynamic of repeated cycles of escalation and de-escalation predicated on the market looks to be alive and well.' Read the original article on Investopedia
Yahoo
31 minutes ago
- Yahoo
Elon Musk calls Donald Trump-backed tax bill a 'disgusting abomination'
Elon Musk has criticised US President Donald Trump's tax and spending bill, calling it "outrageous" and a "disgusting abomination". The bill, which includes multi-trillion-dollar tax breaks, was passed by the House Republicans in May, and has been described by the president as a "big, beautiful bill". The tech billionaire hit out at the tax cuts on his platform X, writing: "This massive, outrageous, pork-filled Congressional spending bill is a disgusting abomination. "Shame on those who voted for it: you know you did wrong. You know it." In American politics, "pork" is a political metaphor used when government spending is allocated to local projects, usually to benefit politicians' constituencies. Musk left the administration abruptly last week after working to cut costs with his team, the newly formed Department of Government Efficiency - known as DOGE - with the ambition of sacking federal workers and cutting red tape. The White House brushed Musk's comments aside, claiming they did not surprise the president. In a press conference on Tuesday, press secretary Karoline Leavitt said that "the president already knows where Elon Musk stood on this bill". She added: "This is one, big, beautiful bill. "And he's sticking to it."
